CKChristian Philipp Kamm

Christian Philipp Kamm

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christian Philipp Kamm has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Home-based training to improve manual dexterity in patients with multiple sclerosis: A randomized controlled trial

    by Christian P Kamm, Heinrich P Mattle, René M Müri, Mirjam R Heldner, Verena Blatter, Sandrine Bartlome, Judith Lüthy, Debora Imboden, Giovanna Pedrazzini, Stephan Bohlhalter, et al.

    Background: Impaired manual dexterity is frequent and disabling in patients with multiple sclerosis (MS), affecting activities of daily living (ADL) and quality of life. Objective: We aimed to evaluate the effectiveness of a standardized, home-based training program to improve manual dexterity and dexterity-related ADL in MS patients. Methods: This was a randomized, rater-blinded controlled trial. Thirty-nine MS patients acknowledging impaired manual dexterity and having a pathological Coin Rotation Task (CRT), Nine Hole Peg Test (9HPT) or both were randomized 1:1 into two standardized training programs, the dexterity training program and the theraband training program. Patients trained five days per week in both programs over a period of 4 weeks. Primary outcome measures performed at baseline and after 4 weeks were the CRT, 9HPT and a dexterous-related ADL questionnaire. Secondary outcome measures were the Chedoke Arm and Hand Activity Inventory (CAHAI-8) and the JAMAR test. Results: The dexterity training program resulted in significant improvements in almost all outcome measures at study end compared with baseline. The theraband training program resulted in mostly non-significant improvements. Conclusion: The home-based dexterity training program significantly improved manual dexterity and dexterity-related ADL in moderately disabled MS patients. Trial Registration NCT01507636.


  • Open Access

    Coin Rotation Task: A Valid Test for Manual Dexterity in Multiple Sclerosis

    by Mirjam R. Heldner, Tim Vanbellingen, Stephan Bohlhalter, Heinrich P. Mattle, René M. Müri, Christian P. Kamm

    Background: Impaired manual dexterity is frequent and disabling in people with multiple sclerosis (MS). Therefore, convenient, quick, and validated tests for manual dexterity in people with MS are needed. Objective: The aim of this study was to validate the Coin Rotation Task (CRT) for examining manual dexterity in people with MS. Design: This was a cross-sectional study. Methods: A total of 101 outpatients with MS were assessed with the CRT, the Expanded Disability Status Scale (EDSS), the Scale for the Assessment and Rating of Ataxia (SARA), and the Modified Ashworth Scale (MAS); muscle strength and sensory deficits of the hands were noted. The concurrent validity and diagnostic accuracy of the CRT were determined by comparison with the 9-Hole Peg Test (9HPT). Construct validity was determined by comparison with a valid dexterity questionnaire. Multiple regression analyses were done to explore correlations of the CRT with the EDSS, SARA, MAS, muscle strength, and sensory deficits. Results: The CRT correlated significantly with the 9HPT (r=.73, P<.0001), indicating good concurrent validity. The cutoff values for the CRT relative to the 9HPT were 18.75 seconds for the dominant hand (sensitivity=81.5%, specificity=80.0%) and 19.25 seconds for the nondominant hand (sensitivity=90.3%, specificity=81.8%); these values indicated good diagnostic accuracy. Furthermore, the CRT correlated significantly with the dexterity questionnaire (r=−.49, P<.0001), indicating moderate construct validity. Multiple regression analyses revealed that the EDSS was the strongest predictor for impaired dexterity. Limitations: Most of the people examined had relapsing-remitting MS and EDSS scores of up to 7. Conclusions: This study validated the CRT as a test that can be used easily and quickly to evaluate manual dexterity in people with MS.


  • Antimyelin antibodies as predictors of disability after clinically isolated syndrome

    by Oliver Findling, Isabelle Durot, Anja Weck, Simon Jung, Christian P. Kamm, Isabell Greeve, Heinrich P. Mattle, Johann Sellner

    There is controversy whether determination of antibodies against myelin, myelin oligodendrocyte glycoprotein, and myelin basic protein in serum from patients with a first episode suggestive of multiple sclerosis is of prognostic value. We evaluated whether detection of antimyelin antibodies in serum indicates a worse course with earlier time to a second relapse and increased progression of disability. We conducted a prospective study at the Department of Neurology, Inselspital Bern, Switzerland from 2004 to 2008 in patients presenting with a clinically isolated syndrome (CIS) and a follow-up of at least 4 months. Antimyelin antibodies were assessed by Western blot. Results were correlated with clinical course and sex. Among 93 consecutive patients with a CIS, 74 (80%) were positive for either one or both antimyelin antibodies. A relapse occurred in 49 (53%) and the median EDSS was 2 (range 1-3.5) after a mean observation period of 20 months. Presence of antimyelin antibodies at CIS neither increased the risk for a second relapse nor for progression of disability. Stratification for gender did not reveal differences for any of the clinical surrogates. The sole determination of antimyelin antibodies in serum is of limited prognostic value for the identification of patients with different short-term course.


  • Reproducibility of sensory nerve conduction studies of the sural nerve using ultrasound‐guided needle positioning

    by Olivier Scheidegger, Alexander F. Küffer, Christian P. Kamm, Kai M. Rösler

    Introduction: In this study we sought to evaluate the reproducibility of sensory nerve conduction studies (NCS) using ultrasound‐guided needle positioning (USNP). Methods: Orthodromic NCS of the sural nerve using needle electrodes with USNP as well as surface electrodes were conducted twice in 20 healthy volunteers. Results: The mean sensory nerve action potential (SNAP) amplitude in the initial examination was 39.5 μV using needle electrodes with USNP, and 12.5 μV using surface electrodes (P < 0.0001). The mean SNAP amplitude in the follow‐up examination was 39.2 μV using needle electrodes with USNP, and 12.4 μV using surface electrodes (P < 0.0001). The mean intraindividual change in SNAP amplitude (test–retest) was 21.2% using needle electrodes with USNP, and 24.8% using surface electrodes (P = 0.6). Conclusions: Sensory NCS of the sural nerve using needle electrodes with USNP have reliable test–retest reproducibility and yield greater SNAP amplitudes than sensory NCS using surface electrodes. Muscle Nerve 2011


  • Open Access

    SWiss Atorvastatin and Interferon Beta-1b Trial In Multiple Sclerosis (SWABIMS) - rationale, design and methodology

    by Christian P Kamm, Heinrich P Mattle, SWABIMS Study Group

    Background: Statins have anti-inflammatory and immunomodulatory properties in addition to their lipid-lowering effects. Currently, the effects of statins on multiple sclerosis are still controversial. Therefore, randomized clinical trials are needed to provide better evidence on the therapeutic potential of statins in multiple sclerosis. The SWiss Atorvastatin and Interferon Beta-1b trial in Multiple Sclerosis (SWABIMS) evaluates the efficacy, safety and tolerability of atorvastatin 40 mg per os daily and subcutaneous interferon beta-1b every other day compared to monotherapy with subcutaneous interferon beta-1b every other day in patients with relapsing-remitting multiple sclerosis. Methods/Design: SWABIMS is a multi-centre, randomized, parallel-group, rater-blinded, Phase IIb-study conducted in eight hospitals in Switzerland. 80 treatment naïve patients with relapsing-remitting forms of multiple sclerosis will receive subcutaneous interferon beta-1b for three months. Afterwards, they are randomized into two equal-sized parallel arms, receiving atorvastatin 40 mg/d or not in addition to interferon beta-1b for another 12 months. Disease activity measured by the proportion of patients with new T2 lesions is the primary endpoint. Discussion: SWABIMS is designed to give further information about the therapeutic effect of atorvastatin 40 mg per os daily as add-on therapy to interferon beta-1b in patients with relapsing-remitting multiple sclerosis. Furthermore important safety and tolerability data will be generated. Trial Registration: http://www.clinicaltrials.gov. Identifier: NCT00942591; Swissmedic reference number: 2005DR2119


  • Campylobacter jejuni abscess, encephalomyelitis, and acute polyradiculoneuropathy

    by Christian Philipp Kamm, Borbala Keserue, Sebastian Humpert, Roland Wiest, Krassen Nedeltchev, Christian Walter Hess, Marcel Arnold

    We report an unusual case of spinal epidural Campylobacter jejuni abscess associated with acute polyradiculoneuropathy and parainfectious encephalomyelitis. Decompressive surgery, antibiotics, intravenous immunoglobulin (IVIg) therapy, and intravenous methylprednisolone resulted in rapid clinical improvement. C. jejuni infection can cause both an acute polyradiculoneuropathy as well as an encephalomyelitis, and a combined occurrence is possible. Muscle Nerve, 2009